Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 4/2012

01-10-2012 | Gynecologic Oncology

Comparison of prognosis in patients with endometrioid endometrial cancer staged IB in FIGO 1988 and 2009 classifications

Authors: Leszek Gottwald, Malgorzata Moszynska-Zielińska, Michal Spych, Jerzy Korczynski, Wieslaw Tylinski, Jaroslaw Szwalski, Robert Kubiak, Grazyna Pasz-Walczak, Janusz Sobotkowski, Jacek Suzin, Janusz Piekarski

Published in: Archives of Gynecology and Obstetrics | Issue 4/2012

Login to get access

Abstract

Purpose

Since 2009 the new FIGO Staging System of endometrial cancer, which changed the previous FIGO 1988 Staging System, has been in use. The aim of the study was to compare prognosis in patients with endometrioid endometrial cancer at stage IB of the 2009 FIGO Staging System and of the 1988 FIGO Staging System.

Methods

We analyzed 173 patients: 108 patients (group A) at stage IB in FIGO 1988 Staging System, and 68 patients (group B) at stage IB in FIGO 2009 Staging System from 262 consecutive endometrioid endometrial cancer patients. The disease-free survival (DFS) and overall survival (OS) were compared between these groups.

Results

The DFS rate was 96.3 % in group A and it was 87.7 % in group B (p = 0.029). Relapses were observed in 12 patients (6.4 %) from 6 to 57 months (mean 28.1; SD = 14.6) after initial surgery, and occurred in four patients from group A (3.7 %) and eight patients from group B (12.3 %) (p = 0.032). The OS rate was 94.4 % in group A and it was 83.1 % in group B (p = 0.018). During follow-up, 17 patients (9.8 %) died: six patients from group A (5.6 %), and 11 patients from group B (16.9 %).

Conclusions

Stage IB in FIGO 2009 Staging System is associated with worse prognosis compared to stage IB according to FIGO 1988 classification. There seems to be a need to use exclusively the new FIGO 2009 classification worldwide to avoid therapeutic mistakes, which can be caused by diverse nomenclature.
Literature
1.
Sivridis E (2004) Endometrial adenocarcinoma: an apostasy from early views. Gynecol Oncol 95:772–777PubMedCrossRef
2.
Cirisano FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL (1999) Epidemiopathologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74:385–394PubMedCrossRef
3.
Kudela M, Pilka R, Lubusky M, Hejtmánek P, Dzubak P, Brychtova S (2011) Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer. Ceska Gynekol 76:194–199PubMed
4.
Maneschi F, Ceccacci I, Perugini A, Pane C, Simeone A, Manicone A (2011) Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings. Arch Gynecol Obstet. doi:101007/​s00404-011-2004-9 PubMed
5.
Odicino F, Pecorelli S, Zigliani L, Creasman WT (2008) History of the FIGO cancer staging system. Int J Gynaecol Obstet 101:205–210PubMedCrossRef
6.
Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines for gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209–262PubMedCrossRef
7.
Shepherd JH (1989) Revised FIGO staging for gynaecological cancer. Brit J Obstet Gynaecol 96:889–892CrossRef
8.
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef
9.
Lewin SN (2011) Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol 54:215–218PubMedCrossRef
10.
Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet 105:109CrossRef
11.
Zaino RJ (2009) FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28:1–9PubMedCrossRef
12.
Korczynski J, Jesionek-Kupnicka D, Gottwald L, Piekarski J (2011) Comparison of FIGO 1989 and 2009 recommendations on staging of endometrial carcinoma: pathologic analysis and cervical status in 123 consecutive cases. Int J Gynecol Pathol 30:328–334PubMedCrossRef
13.
Abu-Rustum NR, Zhou Q, Iasonos A, Alektiar KM, Leitao MM Jr, Chi DS, Sonoda Y, Soslow R, Hensley M, Barakat RR (2011) The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer 21:511–516PubMedCrossRef
14.
Lewin SN, Herzog TJ, Barrena-Medel NI, Deutsch I, Burke WM, Sun X, Wright JD (2010) Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 116:1141–1149PubMedCrossRef
15.
Fanning J (2001) Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 82:371–374PubMedCrossRef
16.
Shumsky AG, Brasher PM, Stuart GC, Nation JG (1997) Risk-specific follow-up for endometrial carcinoma patients. Gynecol Oncol 65:379–382PubMedCrossRef
17.
Lukka H, Chambers A, Fyles A, Thephamongkhol K, Fung-Kee-Fung M, Elit L, Kwon J (2006) Adjuvant radiotherapy in women with stage I endometrial cancer: systematic review. Gynecol Oncol 102:361–368PubMedCrossRef
18.
Goudge C, Bernhard S, Cloven NG, Morris P (2004) The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer. Gynecol Oncol 93:536–539PubMedCrossRef
19.
Gretz HF 3rd, Economos K, Husain A, Lesser M, Kaplan E, Caputo TA, Reynolds RK, Johnston CM, Pearl ML, Roberts JA (1996) The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol 61:409–415CrossRef
20.
Solhjem MC, Petersen IA, Haddock MG (2005) Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. Int J Radiat Oncol Biol Phys 62:1379–1384PubMedCrossRef
21.
Kwon JS, Mazgani M, Miller DM, Ehlen T, Heywood M, McAlpine JN, Finlayson SJ, Plante M, Stuart GC, Carey MS (2011) The significance of surgical staging in intermediate-risk endometrial cancer. Gynecol Oncol 122:50–54PubMedCrossRef
22.
Nout RA, Smit VT, Putter H, Jűrgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial. Lancet 375:816–823PubMedCrossRef
23.
24.
Greven KM, Lanciano RM, Herbert SH, Hogan PE (1991) Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation. Int J Radiat Oncol Biol Phys 21:919–923PubMedCrossRef
25.
Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P (1998) The role of adjuvant radiotherapy in carcinoma of the endometrium: results in 550 patients with pathologic stage I disease. Gynecol Oncol 70:247–254PubMedCrossRef
26.
Cooke EW, Pappas L, Gaffney DK (2011) Does the revised international federation of gynecology and obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes? Cancer. doi:10.​1002/​cncr.​26030
27.
Jordan LB, Al-Nafussi A (2002) Clinicopathological study of the pattern and significance of cervical involvement in cases of endometrial adenocarcinoma. Int J Gynaecol Cancer 12:42–48CrossRef
Metadata
Title
Comparison of prognosis in patients with endometrioid endometrial cancer staged IB in FIGO 1988 and 2009 classifications
Authors
Leszek Gottwald
Malgorzata Moszynska-Zielińska
Michal Spych
Jerzy Korczynski
Wieslaw Tylinski
Jaroslaw Szwalski
Robert Kubiak
Grazyna Pasz-Walczak
Janusz Sobotkowski
Jacek Suzin
Janusz Piekarski
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 4/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2378-3

Other articles of this Issue 4/2012

Archives of Gynecology and Obstetrics 4/2012 Go to the issue

Maternal-Fetal Medicine

Sonographic evaluation of kidney parenchymal growth in the fetus

Letter to the Editor

“Masked uterine rupture”: key to diagnosis

Letter to the Editor

Three-dimensional surface-rendered imaging of cord entanglement in monoamniotic twins

General Gynecology

Risk factors for surgery in patients with tuba-ovarian abscess

General Gynecology

Functional interactions between the fossa ischioanalis, levator ani and gluteus maximus muscles of the female pelvic floor: a prospective study in nulliparous women

Maternal-Fetal Medicine

Type of axial analgesia does not influence time to vaginal delivery in a Proportional Hazards Model